Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707183 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL14985689 | 1.00 | HCRTR1 (0.51) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL18462768 | 0.99 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL13070464 | 0.99 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL2706118 | 0.99 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL2707200 | 0.99 | USP30 (0.52) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL2707224 | 0.97 | HCRTR1 (0.51) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL2757482 | 0.96 | HCRTR1 (0.49) | HCRTR1HCRTR2USP30CHEK2 | |
| SCHEMBL28590669 | 0.95 | USP30 (0.58) | HCRTR1HCRTR2USP30 | |
| SCHEMBL28590668 | 0.95 | USP30 (0.58) | HCRTR1HCRTR2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3002281-B1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3002281-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885USP30 1320/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885USP30 1320/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885USP30 1320/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885USP30 1320/4885 |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885USP30 1320/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885USP30 1320/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | HCRTR1 4298/4885HCRTR2 4654/4885USP30 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.